<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="799623" id="root" date="1997-08-14" xml:lang="en">
<title>USA: TABLE - PharmaPrint Inc results.</title>
<headline>TABLE - PharmaPrint Inc results.</headline>
<dateline>IRVINE, Calif. 1997-08-14</dateline>
<text>
<p>PHARMAPRINT INC.</p>
<p>			   (A development-stage company)</p>
<p>			     STATEMENTS OF OPERATIONS</p>
<p>				 (Unaudited)</p>
<p>			  Three months ended  Period from inception</p>
<p>				   June 30,	    (Sept. 15, 1994)</p>
<p>			     1996	  1997  through Jun 30, 1997</p>
<p> REVENUES			$     --    $     --	$     --</p>
<p>EXPENSES:</p>
<p>  Research and development  385,130   1,029,818     4,775,216</p>
<p>General and administrative</p>
<p>				  2,105,390     803,986    10,119,633</p>
<p>				  2,490,520   1,833,804    14,894,849</p>
<p> LOSS FROM OPERATIONS   (2,490,520) (1,833,804)  (14,894,849)</p>
<p> NET LOSS		   (2,490,520) (1,833,804)  (14,894,849)</p>
<p> LOSS PER SHARE		  (0.30)	(0.16)	  (1.62)</p>
<p>WEIGHTED AVERAGE SHARES</p>
<p>AND EQUIVALENT SHARES</p>
<p>  OUTSTANDING		 8,297,103  11,223,072     9,189,739</p>
<p>				    PHARMAPRINT INC.</p>
<p>			   (A development-stage company)</p>
<p>			  BALANCE SHEET -- JUNE 30, 1997</p>
<p>							     (Unaudited)</p>
<p>ASSETS</p>
<p>CURRENT ASSETS:</p>
<p>  Cash and cash equivalents			    $5,846,828</p>
<p>  Other current assets					343,475</p>
<p>  Total current assets				    6,190,303</p>
<p> EQUIPMENT, NET						 199,136</p>
<p>OTHER ASSETS, net of accumulated</p>
<p>  depreciation and amortization of $12,270	    147,662</p>
<p>  Total assets						6,357,101</p>
<p>LIABILITIES AND SHAREHOLDERS' EQUITY</p>
<p>CURRENT LIABILITIES:</p>
<p>  Accounts payable					    421,566</p>
<p>  Accrued expenses					    182,015</p>
<p>  Total current liabilities				 603,581</p>
<p>COMMITMENTS AND CONTINGENCIES</p>
<p>SHAREHOLDERS' EQUITY:</p>
<p>Preferred stock, $0.001 par value -- 1 million</p>
<p>shares authorized, no shares issued or outstanding Common stock, without par value -- 19 million</p>
<p>shares authorized, 11 million shares</p>
<p>   issued and outstanding				24,653,211</p>
<p>  Additional paid-in capital			    1,130,370</p>
<p>  Deferred compensation				 (4,955,212)</p>
<p>Deficit accumulated during the development</p>
<p>   stage						   (14,894,849)</p>
<p>  Total shareholders' equity			    5,933,520</p>
<p>  Total liabilities and shareholders' equity	6,537,101</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
  <code code="C151">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-08-14"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-08-14"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-08-14"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="IRVINE, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
